Clinical trial
A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes
NCT00883558 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes
- Lead sponsor
- Halozyme Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2009
- Completion date
- April 30, 2010
- Enrollment
- 48 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.